MAIN RESULTS: Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease Circulation. 2022;146:1109–1119. MAIN RESULTS PRESENTATIONS FOURIER Open Label Extension Primary Results (O’Donoghue, ESC 2022) PRESENTATIONS Association Between Achieved LDL-Cholesterol and Long-term Cardiovascular and Safety Outcomes – An Analysis of the FOURIER and FOURIER-OLE Studies (Gaba, AHA 2022) Reduction in Total CV Events with the … Continue reading FOURIER Open Label Extension